In Brief: Sanofi Skelid
Sanofi Skelid: Phase III clinical trials of tiludronate in the treatment of osteoporosis are investigating both 200 mg/day and 50 mg/day doses. Dosage is cyclical, with 7 days of drug followed by 21 days of calcium supplementation. Skelid was approved for treatment of Paget's disease March 7 ("The Pink Sheet" March 17, p. 11)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth